Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

Completed

• Conditions: Colon Cancer

• Registration Number: NCT01310972
• Lead Sponsor: King Faisal Specialist Hospital & Research Center

Brief Summary

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Detailed Description

It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.

Study Timeline

• Study Start: 2007-09
• Primary Completion: 2007-09
• Study Completion: 2007-09
• Study First Submitted: 2011-03-06
• Study First Submitted QC: 2011-03-06
• Study First Posted: 2011-03-09
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-09
• Last Update Posted: 2018-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Patients with Adjuvant Colon Cancer

Exclusion Criteria

• Patients with diagnosis other than Colon Cancer.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OS, PFS, DFS	For the duration of the experiment

Trial Locations

Locations (1)

Kfsh & Rc; 🇸🇦 Riyadh, Saudi Arabia